Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

GE to Expand in Biomedical and Life Sciences with Strategic Acquisitions from Thermo Fisher Scientific

By BiotechDaily International staff writers
Posted on 15 Jan 2014
General Electric (GE; Fairfield, CT, USA) and Thermo Fisher Scientific (Waltham, MA, USA) have entered into an agreement for GE’s subsidiary GE Healthcare (Little Chalfont, UK) to acquire cell culture media and sera, gene modulation, and magnetic beads businesses from Thermo Fisher for approximately USD 1.06 billion. The three businesses to be acquired generated combined annual revenues of approximately USD 250 million in 2013.

GE Healthcare’s leadership in medical diagnostic technology includes its USD 4 billion life sciences business. The acquisition, anticipated to close in early 2014 (subject to regulatory approvals), will allow GE to expand its offering and development of technologies for the discovery and manufacturing of innovative new medicines, cell therapies, vaccines, and diagnostics in the biomedical sector of its growing life sciences division. It will also extend GE’s bioprocessing manufacturing footprint in Asia, the Americas, and Europe.

Thermo Fisher’s HyClone cell culture media and sera products are highly complementary to GE Healthcare’s established technologies for cell biology research and biopharmaceutical manufacturing, enabling GE to offer its customers a substantially wider range of technologies and services. Thermo Fisher’s gene modulation technologies complement GE’s established technologies for drug discovery research, and the Sera-Mag magnetic beads product line extends GE’s existing technologies in protein analysis and medical diagnostics. The complementary product offerings and strong strategic fit of the acquisitions will also enable GE Healthcare to expand and accelerate the development of new “end-to-end” technologies.

“Life sciences is one of our strongest and fastest-growing business areas, driven by the world’s demand for improved diagnostics and new, safer medicines. Combining GE’s engineering expertise with our capabilities in life sciences is already bringing great benefits to industry, research, and patients. This deal [...] will help us realize our vision of bringing better healthcare to more people at lower cost,” said John Dineen, president and CEO, GE Healthcare.

“We look forward to the HyClone cell culture and other businesses joining the GE family. They are a great fit with our key areas of focus, and bring exciting new technologies, enhanced manufacturing capabilities as well as a great group of talented people to help grow our business,” said Kieran Murphy, president and CEO of GE Healthcare’s life sciences division. “In addition to providing us with new approaches to drug discovery and biomedical research, this acquisition is a significant step forward for our customers in biopharmaceutical manufacturing. They will benefit immediately from an expanded range of “start-to-finish” technologies that will help them improve product yields and reduce time-to-market. By expanding our production facilities to three continents, we will be able to offer the biopharmaceutical industry greater confidence in the security of supply of cell culture media and sera.”

Related Links:
General Electric
GE Healthcare
Thermo Fisher Scientific


RANDOX LABORATORIES
BIOSIGMA S.R.L.
SLAS - Society for Laboratory Automation and Screening
comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: The Human Protein Atlas is tissue-based map of the human proteome (Photo courtesy of the Human Protein Atlas).

Open Source Tissue-Based Map of the Human Proteome Launched

Constructed with 13 million annotated images, an interactive database has been created to show the distribution of proteins in all major tissues and organs of the human body. Ten years after the completion... Read more

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel

e-Incubator Technology Provides Real-Time Imaging of Bioengineered Tissues in a Controlled Unit

A new e-incubator, an innovative miniature incubator that is compatible with magnetic resonance imaging (MRI), enables scientists to grow tissue-engineered constructs under a controlled setting and to study their growth and development in real time without risk of contamination or damage. Offering the potential to test... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.